Valneva SE (NASDAQ:VALN) Short Interest Update

Valneva SE (NASDAQ:VALN) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 15,900 shares, a decrease of 34.6% from the December 31st total of 24,300 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 38,300 shares, the short-interest ratio is presently 0.4 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Valneva in a research note on Friday.

Valneva Stock Performance

Shares of VALN traded up $0.52 during trading hours on Friday, hitting $5.77. The stock had a trading volume of 33,952 shares, compared to its average volume of 49,515. Valneva has a 12 month low of $3.62 and a 12 month high of $9.50. The stock has a fifty day moving average price of $4.32 and a 200 day moving average price of $5.72. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The firm has a market capitalization of $468.87 million, a PE ratio of -44.50 and a beta of 1.93.

Institutional Investors Weigh In On Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC grew its holdings in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 118,000 shares of the company’s stock after acquiring an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned about 0.15% of Valneva worth $717,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.